[March 25, 2015]

Research and Markets: Encephalomyelitis Therapeutics Pipeline Review, H1 2015: 7 Companies & 12 Drug Profiles

Research and Markets (http://www.researchandmarkets.com/research/gf95hn/encephalomyelitis) has announced the addition of the "Encephalomyelitis - Pipeline Review, H1 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Encephalomyelitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involve in the therapeutic development for Encephalomyelitis and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

• Effimune SAS (News - Alert)
• Endocyte, Inc.
• Immune Technologies and Medicine
• InteKrin Therapeutics, Inc.
• Io Therapeutics, Inc.
• Merck & Co., Inc.
• Momenta Pharmaceuticals, Inc.

Drug Profiles

• Anatabine
• Antibody for Autoimmune Disorders and Inflammation
• EC-1496
• FR-104
• INT-131
• IRX-5183
• Peptides for Central Nervous System and Musculoskeletal Disorders
• PETIR-001
• PSA-20
• SCH-546738
• Small Molecules to Antagonize VLA-4 for Arthritis, Asthma and Encephalomyelitis
• thymulin

For more information visit http://www.researchandmarkets.com/research/gf95hn/encephalomyelitis

[ Back To TMCnet.com's Homepage ]